AG
DOVA

Aperio Group’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Aperio Group’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-206
Closed -$3K – 3001
2019
Q2 		$3K Buy
+206
New +$1.96K ﹤0.01% 2914

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's DOVA Position: Q3 2019 in Review

Aperio Group sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q3 2019, closing a stake of 206 shares — an estimated $3K sold.

Aperio Group first reported a position in DOVA in Q2 2019 and held it in 1 quarter. The position peaked at $3K in Q2 2019. 72 funds tracked by Wall St. Rank hold DOVA as of Q3 2019.

  • Aperio Group reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 206 Dova Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $3K.
  • Aperio Group first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • Aperio Group's Dova Pharmaceuticals, Inc. Common Stock position peaked at $3K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.